Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (Mayo Clinic)
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
This is an investigational autologous cell therapy developed by the Mayo Clinic, consisting of mesenchymal stem cells (MSCs) derived from a patient's own adipose tissue. The therapy is specifically designed to treat atherosclerotic renovascular disease (ARVD), renovascular hypertension, and associated chronic kidney disease. The treatment involves harvesting MSCs via a fat biopsy, expanding them in vitro, and delivering them through an intra-arterial infusion directly into the renal artery of the affected kidney. The MSCs are thought to exert therapeutic effects through paracrine mechanisms, releasing soluble mediators and extracellular vesicles that promote angiogenesis, reduce inflammation, and facilitate tissue repair. Clinical Phase 1 trials have demonstrated that this infusion can increase renal blood flow, improve glomerular filtration rate (GFR), and decrease inflammatory biomarkers in the stenotic kidney.
- Other names
- autologous adipose-derived MSCsadipose-derived mesenchymal stem cellsMayo Clinic MSC therapy
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (Mayo Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Mayo Clinic).